

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/066,285	02/01/2002	Greg Fahy	074066-0115	3778	
20995	7590 07/02/2003				
	IARTENS OLSON &	EXAMINER			
2040 MAIN STREET FOURTEENTH FLOOR			SAUCIER, SANDRA E		
IRVINE, CA	92614		ART UNIT	PAPER NUMBER	
			1651 DATE MAILED: 07/02/2003	b	

Please find below and/or attached an Office communication concerning this application or proceeding.



Office Action Summary

Application No. 10/066,285

Applicant(s)

Examiner

Fahy et al.

Sandra Saucier

1651



The MAILING DATE of this communication appea	ars on the cover sheet with the correspondence address
Period for Reply	
A SHORTENED STATUTORY PERIOD FOR REPLY IS S THE MAILING DATE OF THIS COMMUNICATION.	ET TO EXPIRE MONTH(S) FROM In no event, however, may a reply be timely filed after SIX (6) MONTHS from the
 Extensions of time may be available under the provisions of 37 CFR 1.136 (a). mailing date of this communication. 	in no event, nowever, may a reply be timely filed after SIX (0) MONTHS from the
 If the period for reply specified above is less than thirty (30) days, a reply with If NO period for reply is specified above, the maximum statutory period will ap Failure to reply within the set or extended period for reply will, by statute, caus Any reply received by the Office later than three months after the mailing date earned patent term adjustment. See 37 CFR 1.704(b). 	ply and will expire SIX (6) MONTHS from the mailing date of this communication. se the application to become ABANDONED (35 U.S.C. § 133).
Status	
1) Responsive to communication(s) filed on	
2a) ☐ This action is FINAL . 2b) ☒ This	action is non-final.
3) Since this application is in condition for allowand closed in accordance with the practice under Ex	e except for formal matters, prosecution as to the merits is parte Quayle, 1935 C.D. 11; 453 O.G. 213.
Disposition of Claims	
4) 💢 Claim(s) <u>1-35</u>	is/are pending in the application.
4a) Of the above, claim(s)	is/are withdrawn from consideration.
5) Claim(s)	is/are allowed.
6)	is/are rejected.
7)	is/are objected to.
8) 💢 Claims <i>1-35</i>	are subject to restriction and/or election requirement.
Application Papers	
9) The specification is objected to by the Examiner.	
10) The drawing(s) filed on is/s	are a) \square accepted or b) \square objected to by the Examiner.
Applicant may not request that any objection to th	e drawing(s) be held in abeyance. See 37 CFR 1.85(a).
11) The proposed drawing correction filed on	is: a) \square approved b) \square disapproved by the Examiner.
If approved, corrected drawings are required in rep	ly to this Office action.
12) The oath or declaration is objected to by the Exa	aminer.
Priority under 35 U.S.C. §§ 119 and 120	
13) Acknowledgement is made of a claim for foreign	n priority under 35 U.S.C. § 119(a)-(d) or (f).
a) \square All b) \square Some* c) \square None of:	
1. Certified copies of the priority documents h	nave been received.
2. Certified copies of the priority documents h	have been received in Application No
application from the International Bo	
*See the attached detailed Office action for a list of	
14) Acknowledgement is made of a claim for domes	
 a) ☐ The translation of the foreign language provision 15) ☒ Acknowledgement is made of a claim for domes 	
	tile priority under 35 0.3.6. 33 120 and/or 121.
Attachment(s) 1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:

Application/Control Number: 10/066285 Page 2

Art Unit: 1651

DETAILED ACTION

Claims 1-35 are pending and subject to restriction.

Election/Restriction

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 7, 8, 19, 20, drawn to a solution comprising polyglycerol, lactose, chondroitin sulfate, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- II. Claims 9-11, drawn to a solution comprising polyglycerol lactose, chlorpromazine, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- III. Claim 12, drawn to a solution comprising polyglycerol lactose, calcium, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- IV. Claim 13, drawn to a solution comprising polyglycerol lactose, citrate, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- V. Claim 14, drawn to a solution comprising polyglycerol lactose, glutathione, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- VI. Claim 15, drawn to a solution comprising polyglycerol lactose, phosphate buffer, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- VII. Claim 16, drawn to a solution comprising polyglycerol lactose, glucose, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- VIII. Claim 17, drawn to a solution comprising polyglycerol lactose, adenine, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- IX. Claim 18, drawn to a solution comprising polyglycerol lactose, magnesium, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.

Application/Control Number: 10/066285

Art Unit: 1651

- X. Claims 21-32, drawn to a method comprising contacting cells, tissue, organ with a polyglycerol solution, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.
- XI. Claims 33-35, drawn to a method comprising contacting cells, tissue, organ with a lactose solution, classified in class 435, subclasses 1.1, 1.2, 1.3, 2 and others.

The inventions are distinct, each from the other because of the following reasons:

Groups I-IX are distinct compositions because they have distinct components and are therefore restrictable.

For example, a composition, A, may not be restricted from compositions A+B, or from A+B+C, or from A+B+C+D as these form a tree of further limitations. However, compositions A+B and A+C and A+D, etc. are distinct compositions and may be properly restricted.

Claims 1-6 are generic and will be examined with elected Group I-IX.

The method of use of Group X does not require the presence of lactose as is required by the compositions of Groups I-IX. Therefore, it is not a method of use of any of the composition Groups I-IX.

The method of use of Group XI does not require the presence of polyglycerol as is required by the compositions of Groups I-IX. Therefore, it is not a method of use of any of the composition Groups I-IX.

The processes of Groups X and XI are distinct from one another because they recite the use of distinct compositions. The process of Group X does not require lactose which is the only component required by the process of Group IX.

The several inventions listed above are independent and distinct from one another as they have acquired a separate status in the art and require independent searches, particularly with regard to the literature searches. Clearly, a reference which would anticipate one of the above groups would not necessarily anticipate or even make obvious any of the others.

Art Unit: 1651

An undue burden would ensue from the examination of multiple methods which have distinct steps and end points. Burden lies not only in the search of US Patents, but in the search for literature and foreign patents and examination of the claim language and specification for compliance with the statutes concerning new matter, distinctness and scope of enablement.

Because these inventions are distinct for the reasons given above restriction for examination purposes as indicated is proper.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1651. The supervisor for 1651 is M. Wityshyn, (703) 308-4743. The normal work schedule for Examiner Saucier is 8:30AM to 5:00 PM Monday and Tuesday and 8:30 to noon on Wednesday.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Saucier whose telephone number is (703) 308–1084. Status inquiries must be directed to the Customer Service Desk at (703) 308–0197 or (703)–308–0198. The number of the Fax Center for the faxing of papers is (703) 308–2742 or (703) 305–3592.

Sandra Saucier Primary Examiner Art Unit 1651 July 1, 2003